Study of SKB103 in HER2-negative Breast Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a Phase I/II clinical study to evaluate the safety and efficacy of SKB103 in participants with advanced (locally advanced, recurrent, or metastatic) HER2-negative breast cancer. The study includes a Phase 1 dose escalation stage and a Phase 2 indication expansion stage.
Epistemonikos ID: 9c17ddd6e5030ce3c2bdb3a96214cf843ff7c7d0
First added on: Aug 19, 2026